Novo Nordisk Faces UK Reprimand for Undisclosed Healthcare Payments

Novo Nordisk Faces UK Reprimand for Undisclosed Healthcare Payments

Danish drugmaker Novo Nordisk has been reprimanded by UK regulators for failing to disclose fees and expenses amounting to approximately $9.97 million, paid to individuals and organisations in Britain between 2020 and 2022. The Prescription Medicines Code of Practice Authority (PMCPA) confirmed that the reprimand followed a voluntary submission by Novo Nordisk, revealing these payments, which involved over 150 different bodies and included fees, expenses to health professionals, sponsorships, and other payments to healthcare organisations.

Novo Nordisk made the voluntary admission in 2023 after identifying historical payments that had not been disclosed. Previously, the company was suspended from the Association of the British Pharmaceutical Industry (ABPI) for two years due to breaches of its code of practice.

Summary

Other news in health